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OBJECTIVES:There is an important heterogeneity in generic penetration among EU
countries. A North-South gradient in generics market share is often quoted with no
reference to policy. Our aim was to compare policies, conditions of penetration and
impact of the generics entries in selected countries to represent large and small,
Northern and Southern, Eastern and Western EU countries. METHODS: We identi-
fied policies and generics market share in volume and value in France, UK, Ger-
many, Poland, Greece, Hungary and Portugal. We browsed websites of EU and
national (when applicable) drug agencies, ministry of health, HTA bodies, payers,
manufacturer unions etc. We completed our research with literature search and
grey reports, as well as Datamonitor reports, IMS data and proprietary pharmavitae
database. RESULTS: There is a wide variability between countries concerning ge-
nerics entry policy. Generics are available from date of their market approval up to
180 days after. Generics prices range from par price to 60% lower than branded
product. In some countries, the generics entries impact the price of the whole class
by regulatory rules, while it may be company free decision in others. In Hungary,
brands are excluded from the market at generic entry. Besides, discount on brands
vary from 0 to 50%. Generic substitution is driven by either local mandatory re-
quirements or financial pharmacist incentives. As a consequence, the generic mar-
ket share varies between 25 to 80% in volume and 20 to 70% in value. The lowest
savings are found in Southern EU while UK and Germany have the largest savings.
Even though Hungary eliminates brands after generic entry, the mix keeps favour-
ing remaining brands in the same class. CONCLUSIONS: Generics policy varies
dramatically from one country to another. This explains the major differences
observed across countries on the drug budget associated with generic entry.
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OBJECTIVES: There has been growing attention for over-medicalization of chil-
dren. We examined trends in outpatient drug use among children in the Nether-
lands from 2005 until 2010. METHODS: The PHARMO Record Linkage System, con-
taining amongst others outpatient pharmacy dispensing data of 3.2 million
inhabitants in the Netherlands, was used for this study. For every year in the study
period 2005-2010, the number of children aged 0-18 with a dispensing for any drug
and per anatomical group was counted and extrapolated to the Netherlands, stan-
dardized for age and gender. Prevalence of use was reported per 10,000 children
and was stratified by calendar year and age group. RESULTS: In all age groups, drug
use increased between 2005-2008, but has been descending since. The highest
increase was found among adolescents (12-18 years): drug use increased from
4,910/10,000 in 2005 to 5,496/10,000 in 2008, but declined to 5,378/10,000 in 2010.
Among infants and toddlers (2 years), use of dermatologicals, anti-infectives,
respiratory drugs and drugs acting on the alimentary tract increased between 2005-
2008. Since 2008, the largest decrease was found for anti-infectives and respiratory
drugs (236 and 136/10,000, respectively). Among children (2-11 years), use of
dermatologicals, neurologicals and drugs acting on the alimentary tract increased
between 2005-2008, while use of anti-infectives decreased (192/10,000). Between
2008-2010, use of anti-infectives kept decreasing (224/10,000). Among adoles-
cents, drug use increased for all anatomical groups between 2005-2008, with the
highest increase for drugs acting on the alimentary tract, respiratory drugs, der-
matologicals and neurologicals. Between 2008-2010, use of neurologicals and drugs
acting on the alimentary tract kept increasing, while use of anti-infectives de-
creased (138/10,000). CONCLUSIONS: Drug use increased between 2005 and 2008,
especially among adolescents, but has been descending since. A substantial in-
crease in use was observed for drugs acting on the alimentary tract, dermatologi-
cals and neurologicals, while the use of anti-infectives decreased over time.
PHP47
DOSE DEPENDENT EVALUATION OF INTESTINAL P-GP ACTIVITY AFTER ONE
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OBJECTIVES: Bacopa monniera has been used as Ayurvedic medicine from time
immemorial to improve memory and intellect. P-glycoprotein expressed in intes-
tinal epithelia is an important efflux transporter that plays an important role in
bioavailability of orally administered drugs. However any modulation in their ac-
tivity results in altered pharmacokinetics of co-administered P-gp substrate drugs.
The aim of this study was to evaluate the dose dependent effect of Bacopa monni-
eraon intestinal P-gp activity after one week oral administration in male Sprague
Dawley rats. METHODS: Modulation in P-gp activity was evaluated by everted gut
sac methodology using digoxin (10 M) as P-gp substrate. Digoxin transported from
mucosal to serosal side of intestine was estimated using HPLC-UV method. Trans-
port of Lucifer yellow (5 M) a cellular integrity marker across intestinal sac was
estimated by fluorescent detector. Viability of tissue was assessed by monitoring
the increase in ratio of glucose transport. RESULTS: Bacopa monniera significantly
inhibited the intestinal P-gp activity by 2.17 (p0.001), 3.67 (p0.001) and 5.25
(p0.001) fold at 15.5, 31 and 62 mg/kg/day dose respectively when compared to
control. Tissue integrity was not disturbed and was found to be viable up to 90
minutes.CONCLUSIONS: Bacopa monniera inhibited the P-gp activity after one week
oral administration. Alteration in P-gp mediated pharmacokinetic parameters
might be possible.
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IRRATIONAL USE OF ANTIBIOTICS IN BALOCHISTAN. A WARNING FOR HEALTH
CARE SYSTEM
Jan SU
University of Balochistan, Quetta, Balochistan, Pakistan
OBJECTIVES: To investigate the irrational prescription habit of antibiotics by med-
ical practitioners in patients of with minor diseases and diarrhea in the area.
METHODS: Eighteen pharmacies were randomly selected in various areas of Ba-
lochistan Province and 402 prescriptions of those patients with complaints of mi-
nor injuries, fever and diarrhea were evaluated for use of antibiotics. RESULTS: 303
out of 402 prescriptions (about 75 %) were containing antibiotics and the patients
with minor injuries, fever and diarrhea were using these mostly in an irrational
manner. These prescriptions were prescribed by medical practitioners of all spe-
cialties including general physicians. A small number of non medical doctors
(about 2%) were also responsible for these prescriptions. These antibiotics were
mainly Flouroquinolones, Aminoglycosides and Beta-Lactams CONCLUSIONS:
This study indicates that this type of irrational practice is the reflection of state and
regulatory affairs in the country and this is a warning for all developing countries
which need strict regulations for antibiotics prescriptions especially when there is
no need.
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OBJECTIVES:To asses and obtain data on the present irrational use and prescribing
habit of medical practitioners for prescribing antibiotics for children in general
symptoms and diarrhea. METHODS: Prescriptions of child patients were analyzed
from May 2010 to March 2012 from 2 public/general Hospitals and 10 private clinics
in different community areas. The data were directly interpreted and analyzed
over the dispensing counters of Pharmacies by Hospital and community
Pharmacists. RESULTS: In public/general hospital 420 out of 560 (75%) patients
were prescribed antibiotics for diarrhea, fever, otitis media and minor injuries,
where as in private clinics 191 out of 210 (91%) of the patients were prescribed at
least one antibiotic for these diseases. The antibiotics were mainly Amoxicillin,
Co-amoxiclav, Ciprofloxacin, Norfloxacin and Flouroquinolones. It was also ob-
served that in some cases the antibiotics of choice was not recommended. This
irrational prescribing habit of the medical practitioners was observed everywhere
in the area both in public Hospitals and in private clinics. CONCLUSIONS: This
study showed that the irrational antibiotic use in children is a common practice
which is an alarming situation and needs strict regulatory strategies for control.
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OBJECTIVES: Risk adjustment models allow stratifying the population, considering
chronic disease as a predictor of drug costs. In this paper, we analyze outpatient
drug spending using Clinical Risk Groups (CRG) to obtain patient risk stratification.
METHODS: The study included 5,248,276 patients living in Valencian Community.
The classification of patients was carried out using CRG. The necessary information
was obtained from existing records in the database of Primary Health Care (PHC)
pharmaceutical information system GAIA, and the computer application ABUCA-
SIS. We analyzed the predictive power of the model using regression analysis,
taking as the dependent variable the neperian logarithm of the annual PHC drug
costs per patient, and as independent variables the health status of patients, de-
mographic characteristics, use of health system. RESULTS: The CRG3 groups 5 and
6 represent a 74, 4% of total pharmaceutical spending while patients in this group
are only 25% of the total. The system of grouping patients CRG3 is a good predictor
of drug expenditures, except for the CRG3 groups 8 and 9 The model obtained could
be a useful tool for managing pharmaceutical budget policies and patient
management.CONCLUSIONS:To use the CRG3 grouping system is generally a good
estimator of pharmaceutical expenditure in primary care. However, the CRG3
groups should be adjusted according to their pharmaceutical expenditure in hos-
pital pharmacy.
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PERCEPTION OF PARALLEL TRADE OF PHARMACEUTICALS IN POLAND –
RESULTS OF NATIONAL MARKET RESEARCH
Baran-Lewandowska I, Hermanowski T
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OBJECTIVES: Conduct qualitative and quantitative surveys and evaluate the per-
ception of parallel trade (PT) of pharmaceuticals among pharmacists and consum-
ers in Poland; learn about experiences concerning PT phenomenon; develop and
verify hypotheses concerning potential PT risks and opportunities. METHODS: In-
dividual in-depth interview (IDI) and focus group interview (FGI) with PT experts,
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direct interviews and auditorium/e-mail/internet/postal surveys among pharma-
cists (28/27 questions for public pharmacies (PP)/hospital pharmacies (HP) respec-
tively) and consumers (13 questions). RESULTS: The survey was conducted be-
tween May and October 2011 among PP (N958) and HP (N91). 38.1 % PP and 59.3%
HP confirmed that the level of their knowledge of PT is definitely unsatisfactory and
requires substantial broadening. The majority of pharmacists believe medicines
from PT to be as safe as other medicines (83.4 %/74.2% PP/HP respectively). Almost
40% of pharmacists agree that the introduction of PT medicines has increased
competitive pressure and contributed to a decrease in the prices of medicines
registered using other regulatory procedures. Pharmacists indicated that the most
desired solutions which would support the PT development in Poland are a nation-
wide information campaign concerning PT and training for pharmacists on the
legal and economic aspects. The survey among consumers revealed that 90% of
respondents had not ever heard about PT. 51% of consumers indicated that lower
price is the most important factor in convincing them to purchase PT medicines.
CONCLUSIONS: Pharmacists have limited knowledge about PT. There is a strong
need for training directed at pharmacists. The hospital market is still under-ex-
plored in Poland and therefore represents a very attractive opportunity for the PT
development. Only 10% of consumers are familiar with the PT concept which re-
veals the urgent need for a nationwide campaign to highlight the issue of PT.
Product price is the most important incentive for consumers that in convincing
them to purchase PT products.
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THE CARDIOVASCULAR DRUG UTILISATION IN CROATIA IN THE PERIOD 2007-
2010, TRENDS AND PERSPECTIVES
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OBJECTIVES:An extensive insight into drug utilization as an economic and a public
health issue can only be obtained when related to the integrated health state of the
respective population.Our target is to investigate the utilization trends of cardio-
vascular drugs in Croatia during the period 2007- 2010, thus focusing on the most
common pharmacological/therapeutic subgroups. This allows us to make direct
comparisons with the number of patient’s hospital admissions connected to car-
diovascular events. METHODS: The data of drug utilization in Croatia is collected
and analyzed by the Croatian Agency for Medicinal Products and Medical Devices
HALMED. By applying the Anatomical-Therapeutic-Chemical methodology (ATC),
the given data is used to calculate the number of defined daily doses (DDD) and
DDD per 1000 inhabitants per day (DDD/1000/day) between 2007-2010, whereas the
data of hospital statistics is analyzed by The Public Health Institute. RESULTS: The
utilization of all cardiovascular drugs indicate an increase of 47.55% (from 248.88
DDD/1000/day in 2007 to 367.23 DDD/1000/day in 2010), while the total cost in-
creased for 13.09% (from 863,601,721 KN in 2007 to 976,657,904 KN in 2010). The
utilization of the lipid modifying agents (C10) increased the most (78.93%), followed
by agents acting on the renin-angiotensin system (57.51%) and succeeded by cal-
cium channel blockers (28.46%). The total number of hospital admissions related to
cardiovascular diseases decreased from 84,413 in 2007 to 81,575 in 2010.
CONCLUSIONS:During the period 2007-2010 the utilization of cardiovascular drugs
increased significantly. In the same period the number of hospital admissions of
the patients with main cardiovascular events (3.4%) indicated a decrease. It is
necessary to undertake further analysis of these co-founders.
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OBJECTIVES: In Malaysia public sector, medicines spending in Ministry of Health
health facilities has increased by 428% from 1998 to 2008. The ultimate aim of this
research is to examine the trend of medicine expenditure and to identify the fac-
tors associated with the changes in medicine expenditure. METHODS: This was a
cross-sectional study. It studied prescriptions from 2007 to 2009 at the Pharmacy
Department of SFMS Hospital in Johor State. Simple linear regression and multiple
linear regression analysis were conducted. RESULTS: Total medicines expendi-
tures for outpatient and inpatient rose every year. In outpatient, volume of medi-
cine utilization increased over the years. Medicine expenditure declined in 2009
despite the continuous rise of medicines utilization. Median cost per medicine
declined throughout these three years. Inpatient had a continuous rise in medicine
expenditure. Median cost per medicine was fluctuating between 2007 and 2009 and
was about 35% lower than outpatient. In outpatient, median cost per medicine was
significantly different between years 2007, 2008 and 2009 for all variables except for
hospital discipline Paediatric and X-ray. Meanwhile in inpatient, the exception was
for Dermatology, X-ray, Ophthalmology and Dental. The study found that volume
of medicine utilization, which includes the number of medicines, number of med-
icines per prescription and duration of supply, contributed significantly to the
increase of medicine expenditure. Demographics, price and new medicine ap-
proved in the formulary were found to have no impact. CONCLUSIONS: The in-
crease of medicine utilization rate could be due to the increase of population; the
increase of the elderly population and new treatment guidelines and treatment
which was previously not available. Other factors include off-label prescribing,
irrational prescribing and poly-pharmacy. These three factors can lead to medica-
tion wastage and higher cost of treatment. Duration of medicine supply must be
carefully monitored as longer duration might result in medication wastage.
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OBJECTIVES: The signing of the TRIPS agreement in 1995 and Doha Declaration in
2001 have allowed low and middle-income countries to issue compulsory licenses
(CLs) for medicines in times of national emergency. While normally for infectious
diseases, given the epidemiologic transition occurring in these countries along
with the development of insurance systems, it is likely that the trend in the next
decade will be towards a higher demand for more expensive medicines to treat
non-communicable diseases (NCDs). We sought to determine the impact of CLs for
medicines that treat NCDs and make recommendations as to how pharmaceutical
companies and governments can work together in the future. METHODS: We ana-
lysed a series of cases where a CL was issued, or the manufacturer successfully
negotiated to retain patent rights for drugs treating NCDs to determine the relative
impact of the CL or negotiations, prices were benchmarked and compared before
and after CL issuance in 2012 US dollars using the medical commodities consumer
price index and relevant exchange rates. RESULTS: Of nine CL cases identified, six
resulted in an issued license, two were withdrawn, and one was negotiated and
resulted in a discount and cost sharing agreement. For licenses issued, the average
price reduction was 86.2% and supply was issued to a generics manufacturer.
Roche recently decreased the prices of three of its products by an average of 91.0%
in India - indicating there may be a trend to reducing price in order to protect patent
rights and avoid CL issuance. CONCLUSIONS: Low-income countries are increas-
ingly using CLs to obtain lower prices for medicines to treat NCDs. Price negotiation
tended to result in a greater price decrease than issued CLs, highlighting the im-
portance placed on retaining patent rights. Pharma companies could consider pro-
actively seeking cost-sharing arrangements to provide access to low-income pa-
tients and maintain market exclusivity.
HEALTH CARE USE & POLICY STUDIES - Equity And Access
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HORIZONTAL EQUITY IN PRIMARY HEALTH CARE SERVICES IN TIMES OF
ECONOMIC CRISIS IN GREECE: EX ANTE AND EX POST FINDINGS
Zavras D, Kyriopoulos II, Pavi E, Kyriopoulos J
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OBJECTIVES: To investigate the horizontal equity concerning the use of primary
health care services in Greece in 2006 and in 2011. Given that the economic crisis
affects the health care system in Greece, the comparison between the findings
depicts the post-crisis effects on the use of primary health care services.
METHODS: The research is based on two cross-sectional surveys, which took place
in 2006 and in 2011, and the sample size was 4003 and 6569 respectively. Moreover,
a random, stratified sampling was applied in both cases, which took into account
the age, the gender, the urbanization rate and the geographical region. RESULTS:
The Concentration Index for the measurement of horizontal equity (CHE) can be
estimated as CU-CN. The CU index depicts the use of primary health care services,
based on the number of medical visits. Additionally, the CN index intends to specify
the use of primary health care services in terms of need for care. It is also notewor-
thy that CN was estimated after applying the Poisson Regression method (depen-
dent variable: use of primary health care services, independent variables: self as-
sessed health status and chronic health problems). According to the results, CHE
was 0.06 in 2006, as CU and CN were estimated at 0.14 and 0.08 respectively.
Furthermore, CU was0.06, while CN was estimated at0.04 in 2011. Therefore CHE
decreased to 0.02. CONCLUSIONS: The low-income individuals tend to use pri-
mary health care services more than the high-income individuals, regardless the
economic crisis. This finding can be explained, as the low income is usually accom-
panied with a lower health status. Generally, as CHE is close to zero, there are not
strong indications of inequality. However, CHE increased in 2011 (closer to zero),
which implies that the inequality shifted from higher income individuals.
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EMERGING DRUG REIMBURSEMENT MODELS: LESSONS AND IMPLICATIONS
FROM CANCER DRUG ACCESS SCHEMES
Aggarwal S
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OBJECTIVES: Cancer drugs are the world’s highest selling category of therapeutic
products. Due to their premium price and budget impact, several new drug reim-
bursement models have been implemented worldwide by public and private pay-
ers. These models have potential implications for coverage and reimbursement of
all branded products. This study reviewed recent cancer drug reimbursement mod-
els and developed lessons and implications for future products. METHODS: Re-
viewed cancer drug reimbursement schemes in developed and emerging markets.
Interviewed payers and KOLs to develop lessons and implications for future
products. RESULTS: Public and private payers worldwide have implemented sev-
eral new models for cancer drug reimbursement to manage budgets and control
costs. In the US, private payers are piloting single source compendia and third party
protocols (eg. P4 Oncology) to limit off-label use of cancer drugs. In the UK, NICE has
successfully negotiated lower price and discounts for first few cycles of therapy. In
Italy, AIFA has implemented registry based patient access for cancer drugs. In
India, several manufacturers have implemented novel pricing strategy for first few
cycles of therapy. In Germany, IQWIG has proposed to use correlations between
surrogate endpoints and patient relevant outcomes to determine value of cancer
drugs. Due to increased cost pressure on payers, such models are likely to inspire
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